Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Study

NCT04770623 is registered in ClinicalTrials.gov with Menoufia University as lead sponsor.

NCT NCT04770623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Study
Lead sponsor
Menoufia University
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2021
Completion date
January 9, 2023
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, gastric cancer, stomach cancer